In this interview, Mark Burkard, MD, PhD, discusses the Molecular Tumor Board program at the University of Wisconsin Carbone Cancer Center and the impact it's making for advanced cancer patients.
In light of the recent announcement by Vice President Joe Biden to infuse the US cancer research program with $1 billion, a so-called “Moon Shot” program, we are speaking today with Giulio Draetta, a clinician and cancer researcher at MD Anderson Cancer Center at the University of Texas in Houston, who leads that center’s Moon Shots program.
We are speaking with Maximilian Diehn, MD, PhD, on developing genomics-based biomarkers to identify the presence of cancer cells for prognosis and predicting response to cancer therapies.
Ahead of the 57th ASH Annual Meeting & Exposition, December December 5–8, 2015, Nitin Jain, MD, discusses the cost burden associated with targeted therapy use in the CLL population.
Ahead of the 57th ASH Annual Meeting & Exposition, December 5–8, 2015, Jeffrey Tyner, PhD, discusses his latest research on screening tumor cells derived from cancer patients to help guide better treatment decisions.
Ahead of the 2015 ASCO Breast Cancer Symposium, Saima Noor Hassan, MD, PhD, discusses her upcoming presentation on PARP inhibitors in breast cancer.
In this interview, researchers discuss their analysis of a specific type of acute myeloid leukemia.
In this interview, Dr. Sumithra J. Mandrekar talks about umbrella versus basket trials in lung cancer.
In this interview, Dr. Mario Eisenberger talks about potential new combination therapies for advanced prostate cancer that are currently being tested in clinical trials.
As part of our 2015 ASCO Annual Meeting coverage, we discussed immunotherapy combinations in advanced melanoma patients with Michael A. Postow, MD.